Traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, pharmaceutical preparation and preparation method and application thereof

Abstract

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, a pharmaceutical preparation and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 5 to 18 parts of rhizoma coptidis, 5 to 18 parts of rhizoma zingiberis, 4 to 15 parts of radix scutellariae, 5 to 18 parts of rhizoma pinelliae, 9 to 27 parts of radix astragali seu hedysari, 5 to 18 parts of radix codonopsis, 5 to 18 parts of rhizoma atractylodis macrocephalae, 5 to 18 parts of herba dendrobii, 5 to 18 parts of radix curcumae, 5 to 18 parts of radix salviae miltiorrhizae, 5 to 18 parts of rhizoma curcumae, 10 to 30 parts of herba hedyotidis diffusae and 5 to 18 parts of fructus aurantii immaturus. The traditional Chinese medicine composition provided by the invention can effectively block, slow down and reverse the chronic atrophic gastritis with intestinal metaplasia'inflammation-cancer transformation 'process, and is low in cost, small in side effect and high in patient compliance.

Description

Technical Field

[0001] The present application relates to the field of traditional Chinese medicine, and more specifically, to a traditional Chinese medicine composition, a pharmaceutical preparation, and a preparation method and application thereof for treating chronic atrophic gastritis with intestinal metaplasia. Background Art

[0002] Chronic atrophic gastritis (CAG) is a common digestive disease characterized by atrophy and decreased number of gastric mucosal epithelium and glands, thinning of the gastric mucosa, and thickening of the mucosal basal layer. Key symptoms include upper abdominal distension and pain, belching, and acid reflux. The etiology of CAG remains unclear, but it has long been linked to Helicobacter pylori infection, bile reflux, immune dysfunction, age, high salt intake, excessive heat, a low-vitamin diet, and genetic factors, representing a complex interplay of factors. As the disease progresses, CAG may be accompanied by intestinal metaplasia (IM). IM refers to the transformation of the gastric mucosal epithelium into small or large intestinal epithelial tissue containing Pannett cells or goblet cells, a key step in the "inflammatory-to-cancer" transformation of CAG. Blocking, slowing, and reversing this "inflammatory-to-cancer" transformation in CAG remains a common challenge facing both traditional Chinese and Western medicine.

[0003] Currently, because the pathogenesis of CAG with IM is not fully understood, there is no recognized treatment for CAG with IM in Western medicine. Most treatments are symptomatic, including anti-inflammatory, antibacterial, acid-suppressing, digestive, and mucosal protective therapies. Follow-up observation is performed until high-grade intraepithelial neoplasia develops, followed by surgical treatment, but there is still a risk of recurrence after surgery. Patent No. CN115518142A discloses a traditional Chinese medicine composition for preventing and treating atrophic gastritis and its use. The composition includes: 10g of Pinellia ternata, 10g of Scutellaria baicalensis, 8g of Coptis chinensis, 10g of Dried Ginger, 10g of Curcuma aromatica, 10g of stir-fried Atractylodes lancea, 10g of stir-fried Atractylodes macrocephala, 15g of Astragalus membranaceus, 20g of Hedyotis diffusa, 20g of Scutellaria barbata, 10g of Salvia miltiorrhiza, 10g of Dendrobium candidum, 10g of Pseudostellaria pseudoginseng, 6g of stir-fried Barley sprout, 6g of stir-fried Malt, 10g of Citrus aurantium immaturus, 10g of Magnolia officinalis, 10g of Curcuma zedoaria, 3g of fresh ginger, and 6g of jujube. The above-mentioned Chinese medicine composition includes 20 single drugs. The large number of single drugs leads to problems such as high cost, increased adverse reactions, and poor patient compliance. Summary of the Invention

[0004] In order to solve the problems in the prior art of using traditional Chinese medicine to treat chronic atrophic gastritis with intestinal metaplasia, such as the large number of single drugs leading to high costs, increased adverse reactions, and poor patient compliance, the present invention aims to provide a traditional Chinese medicine composition, a pharmaceutical preparation, and a preparation method and application thereof for treating chronic atrophic gastritis with intestinal metaplasia, which has the advantages of simplified formula, reasonable selection of raw materials, and comprehensive efficacy, and the effect of treating chronic atrophic gastritis with intestinal metaplasia is greatly improved.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia. The composition comprises the following components in proportion by weight: 5-18 parts of coptis chinensis, 5-18 parts of dried ginger, 4-15 parts of scutellaria baicalensis, 5-18 parts of pinellia ternata, 9-27 parts of astragalus membranaceus, 5-18 parts of codonopsis pilosula, 5-18 parts of atractylodes macrocephala, 5-18 parts of dendrobium officinale, 5-18 parts of turmeric, 5-18 parts of salvia miltiorrhiza, 5-18 parts of zedoaria, 10-30 parts of oldenlandia diffusa herb, and 5-18 parts of immature aurantium.

[0007] Specifically, in some embodiments of the present invention, the above-mentioned traditional Chinese medicine composition includes the following components in proportions by weight: 6-14 parts of coptis chinensis, 6-14 parts of dried ginger, 5-11 parts of scutellaria baicalensis, 6-14 parts of pinellia ternata, 11-19 parts of astragalus membranaceus, 6-14 parts of codonopsis pilosula, 6-14 parts of atractylodes macrocephala, 6-14 parts of dendrobium, 6-14 parts of turmeric, 6-14 parts of salvia miltiorrhiza, 6-14 parts of zedoaria, 15-25 parts of oldenlandia diffusa, and 6-14 parts of immature bitter orange.

[0008] Specifically, in some embodiments of the present invention, the above-mentioned traditional Chinese medicine composition comprises the following components in the following weight ratios:

[0009] 10 parts of Coptis chinensis, 10 parts of dried ginger, 8 parts of Scutellaria baicalensis, 10 parts of Pinellia ternata, 15 parts of Astragalus membranaceus, 10 parts of Codonopsis pilosula, 10 parts of Atractylodes macrocephala, 10 parts of Dendrobium candidum, 10 parts of Curcuma aromatica, 10 parts of Salvia miltiorrhiza, 10 parts of Curcuma zedoaria, 20 parts of Hedyotis diffusa, 10 parts of Citrus aurantium; or

[0010] 9 parts of Coptis chinensis, 6 parts of Dry Ginger, 6 parts of Scutellaria baicalensis, 6 parts of Pinellia ternata, 9 parts of Astragalus membranaceus, 6 parts of Codonopsis pilosula, 6 parts of Atractylodes macrocephala, 6 parts of Dendrobium candidum, 6 parts of Curcuma aromatica, 6 parts of Salvia miltiorrhiza, 6 parts of Curcuma zedoaria, 12 parts of Hedyotis diffusa, 6 parts of Citrus aurantium; or

[0011] 12 parts of Coptis chinensis, 12 parts of dried ginger, 12 parts of Scutellaria baicalensis, 12 parts of Pinellia ternata, 17 parts of Astragalus membranaceus, 8 parts of Codonopsis pilosula, 8 parts of Atractylodes macrocephala, 8 parts of Dendrobium candidum, 8 parts of Curcuma aromatica, 8 parts of Salvia miltiorrhiza, 8 parts of Curcuma zedoaria, 18 parts of Hedyotis diffusa, 8 parts of Citrus aurantium; or

[0012] 8 parts of Coptis chinensis, 8 parts of dried ginger, 6 parts of Scutellaria baicalensis, 8 parts of Pinellia ternata, 13 parts of Astragalus membranaceus, 12 parts of Codonopsis pilosula, 12 parts of Atractylodes macrocephala, 12 parts of Dendrobium candidum, 12 parts of Curcuma aromatica, 12 parts of Salvia miltiorrhiza, 12 parts of Curcuma zedoaria, 22 parts of Hedyotis diffusa, and 12 parts of Citrus aurantium.

[0013] Specifically, in some embodiments of the present invention, in the above-mentioned traditional Chinese medicine composition, the pinellia is clear pinellia, and the atractylodes is stir-fried atractylodes.

[0014] The present invention also provides a method for preparing the above-mentioned Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, which comprises:

[0015] The Chinese medicinal raw materials in the formula amount are weighed respectively, decocted in water for extraction, filtered, the filtrates are combined, concentrated under reduced pressure, dried, and auxiliary materials are added to obtain the product.

[0016] Specifically, in some embodiments of the present invention, the Chinese medicinal raw materials are soaked for 0.5-4 hours before extraction, the weight of water added for decoction is 5-10 times the weight of the Chinese medicinal raw materials, the number of extractions is 2-4 times, and the extraction time each time is 0.5-2 hours.

[0017] The present invention also provides a pharmaceutical preparation of the Chinese medicine composition obtained by the above-mentioned Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and / or a preparation method of the above-mentioned Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, wherein the pharmaceutical preparation comprises the Chinese medicine composition and excipients.

[0018] Specifically, in some embodiments of the present invention, the dosage forms of the pharmaceutical preparation include tablets, capsules, powders, granules, ointments, oral liquid preparations, suppositories, injections, inhalants, gels, microspheres, and aerosols.

[0019] The present invention also provides the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and / or the preparation method of the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, and the use of the obtained traditional Chinese medicine composition in preparing medicines and / or preparations for preventing and / or treating chronic atrophic gastritis.

[0020] The present invention also provides the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and / or the preparation method of the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, and the use of the obtained traditional Chinese medicine composition in preparing drugs and / or preparations for preventing and / or treating intestinal metaplasia.

[0021] In summary, this application has the following beneficial effects:

[0022] 1. Compared with the prior art CN115518142A patent, which includes 20 single drugs, the large number of single drugs leads to high costs, increased adverse reactions, and poor patient compliance. The present invention creatively combines 13 single drugs in a reasonable combination, achieving synergistic effects between the components, optimizing and reducing the number and types of single drugs. By adding Codonopsis pilosula and removing Atractylodes lancea, Scutellaria barbata, Pseudostellaria zizi, barley sprout, malt, Magnolia officinalis, ginger, and jujube, and limiting the dosage ratio, significant technological progress has been achieved. The technological progress specifically involves reducing costs, improving efficacy, reducing side effects, and improving patient compliance.

[0023] 2. The present invention creatively uses Qing Banxia instead of the commonly used processed Pinellia, which has a better effect. It is generally believed that processed Pinellia is less toxic than Qing Banxia, but the inventors have found in clinical practice that Qing Banxia is mainly used to treat spleen and stomach diseases, and its effect of reducing adverse reactions and eliminating abdominal distension is stronger. Qing Banxia is more effective in treating chronic atrophic gastritis with intestinal metaplasia.

[0024] 3. Based on clinical practice, the present invention has found the optimal weight ratio relationship, so that the entire prescription is reasonably compatible with the monarch, minister, adjuvant and envoy, and exerts the best therapeutic effect;

[0025] 4. The present invention creatively combines 13 single drugs in a reasonable combination, so that the components act synergistically. The Chinese medicine composition has the effects of promoting qi and relieving abdominal distension, replenishing qi and nourishing yin, and removing blood stasis and detoxifying. It has significant clinical effects in preventing and treating chronic atrophic gastritis with intestinal metaplasia, especially for patients with epigastric distension and pain, belching, acid reflux, noisy stomach, poor appetite, fatigue, irritability, dry mouth and bitter taste, red tongue with yellow fur or ecchymosis, and deep and stringy pulse caused by spleen deficiency and qi stagnation, insufficient stomach yin, mixed cold and heat, and mutual toxicity and blood stasis. It can effectively block, slow down, and reverse the "inflammation-cancer transformation" process of chronic atrophic gastritis with intestinal metaplasia. DETAILED DESCRIPTION

[0026] The invention discloses a traditional Chinese medicine composition, a preparation method and application thereof.

[0027] It should be understood that the expression "one or more of" includes individually each of the items recited after the expression and various combinations of two or more of the recited items, unless otherwise apparent from the context and usage. The expression "and / or" in conjunction with three or more recited items should be understood to have the same meaning, unless otherwise apparent from the context.

[0028] The terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, e.g., not excluding other unrecited elements or steps, unless otherwise specifically stated or understood from the context.

[0029] It should be understood that the order of steps or the order in which certain actions are performed are not important as long as the present invention remains operable. Additionally, two or more steps or actions may be performed simultaneously.

[0030] The use of any and all examples or exemplary language, such as "such as" or "including," herein is intended merely to better illustrate the invention and does not limit the scope of the invention unless otherwise claimed. No language in this specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0031] In addition, the numerical ranges and parameters used to define the present invention are approximate values. The relevant numerical values in the specific examples have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual testing methods. Therefore, unless otherwise expressly stated, all ranges, amounts, values, and percentages used in this disclosure should be understood to be modified by the word "about." As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a specified value or range.

[0032] The Chinese medicinal raw materials used in the present invention are all conventional raw materials in the art, and their corresponding plant sources and medicinal parts are all known and common. The reagents used in the present invention can all be purchased from the market.

[0033] The present invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia. The composition comprises the following components in proportion by weight: 5-18 parts of coptis chinensis, 5-18 parts of dried ginger, 4-15 parts of scutellaria baicalensis, 5-18 parts of pinellia ternata, 9-27 parts of astragalus membranaceus, 5-18 parts of codonopsis pilosula, 5-18 parts of atractylodes macrocephala, 5-18 parts of dendrobium officinale, 5-18 parts of turmeric, 5-18 parts of salvia miltiorrhiza, 5-18 parts of zedoaria, 10-30 parts of oldenlandia diffusa herb, and 5-18 parts of immature aurantium.

[0034] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of coptis chinensis, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0035] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of dried ginger, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0036] The traditional Chinese medicine composition provided by the present invention comprises 4-15 parts by weight of Scutellaria baicalensis, preferably 5-14 parts by weight, and more preferably 6-13 parts by weight.

[0037] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of Pinellia ternata, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0038] The traditional Chinese medicine composition provided by the present invention comprises 9-27 parts by weight of Astragalus membranaceus, preferably 10-26 parts by weight, and more preferably 11-25 parts by weight.

[0039] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of Codonopsis pilosula, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0040] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of Atractylodes macrocephala, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0041] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of dendrobium, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0042] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of Curcuma aromatica, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0043] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of Salvia miltiorrhiza, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0044] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of Curcuma zedoaria, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0045] The traditional Chinese medicine composition provided by the present invention comprises 10-30 parts by weight of Hedyotis diffusa, preferably 11-29 parts by weight, and more preferably 12-28 parts by weight.

[0046] The traditional Chinese medicine composition provided by the present invention comprises 5-18 parts by weight of Citrus aurantium immaturum, preferably 6-17 parts by weight, and more preferably 7-16 parts by weight.

[0047] In one preferred embodiment of the present invention, the above-mentioned traditional Chinese medicine composition includes the following components in proportions by weight: 6-17 parts of coptis chinensis, 6-17 parts of dried ginger, 5-14 parts of scutellaria baicalensis, 6-17 parts of pinellia ternata, 10-26 parts of astragalus, 6-17 parts of codonopsis pilosula, 6-17 parts of atractylodes macrocephala, 6-17 parts of dendrobium, 6-17 parts of turmeric, 6-17 parts of salvia miltiorrhiza, 6-17 parts of zedoaria, 11-29 parts of oldenlandia diffusa, and 6-17 parts of immature bitter orange.

[0048] In one preferred embodiment of the present invention, the above-mentioned traditional Chinese medicine composition includes the following components in proportions by weight: 7-16 parts of coptis chinensis, 7-16 parts of dried ginger, 6-13 parts of scutellaria baicalensis, 7-16 parts of pinellia ternata, 11-25 parts of astragalus, 7-16 parts of codonopsis pilosula, 7-16 parts of atractylodes macrocephala, 7-16 parts of dendrobium, 7-16 parts of turmeric, 7-16 parts of salvia miltiorrhiza, 7-16 parts of zedoaria, 12-28 parts of oldenlandia diffusa, and 7-16 parts of immature bitter orange.

[0049] In one preferred embodiment of the present invention, the above-mentioned traditional Chinese medicine composition includes the following components in proportions by weight: 6-14 parts of coptis chinensis, 6-14 parts of dried ginger, 5-11 parts of scutellaria baicalensis, 6-14 parts of pinellia ternata, 11-19 parts of astragalus, 6-14 parts of codonopsis pilosula, 6-14 parts of atractylodes macrocephala, 6-14 parts of dendrobium, 6-14 parts of turmeric, 6-14 parts of salvia miltiorrhiza, 6-14 parts of zedoaria, 15-25 parts of oldenlandia diffusa, and 6-14 parts of immature bitter orange.

[0050] In one preferred embodiment of the present invention, the above-mentioned traditional Chinese medicine composition includes the following components in proportions by weight: 8-12 parts of coptis chinensis, 8-12 parts of dried ginger, 6-10 parts of scutellaria baicalensis, 8-12 parts of pinellia ternata, 13-17 parts of astragalus, 8-12 parts of codonopsis pilosula, 8-12 parts of atractylodes macrocephala, 8-12 parts of dendrobium, 8-12 parts of turmeric, 8-12 parts of salvia miltiorrhiza, 8-12 parts of zedoaria, 18-22 parts of oldenlandia diffusa, and 8-12 parts of immature bitter orange.

[0051] In some preferred embodiments of the present invention, in the above-mentioned traditional Chinese medicine composition, the pinellia is clear pinellia, the atractylodes is stir-fried atractylodes, the immature tangerine peel is stir-fried immature tangerine peel, and the zedoaria is vinegared zedoaria. It should be noted that if the processing specifications are not specified in the prescription, all are used as raw products.

[0052] The processed products selected in the present invention are all obtained through a large amount of clinical practice and / or pharmacodynamic experiments, and are the most effective among various processed products of similar Chinese medicinal raw materials, and can exert the best therapeutic effect in treating functional dyspepsia.

[0053] The traditional Chinese medicine composition of the present invention has the effects of promoting qi circulation, relieving abdominal distension, replenishing qi and nourishing yin, and removing blood stasis and detoxifying. It is used to treat epigastric distension and pain, belching, acid reflux, noisy stomach, poor appetite, fatigue, irritability, dry mouth and bitter taste, red tongue with yellow fur or ecchymosis, and deep and stringy pulse caused by spleen deficiency and qi stagnation, insufficient stomach yin, mixed cold and heat, and toxic blood stasis; and for chronic atrophic gastritis with intestinal metaplasia presenting with the above symptoms.

[0054] The inventors of this application have conducted extensive research based on the theory of traditional Chinese medicine formulation, modern pharmacology and clinical practice, and thus obtained the traditional Chinese medicine composition for treating functional dyspepsia described in this application, which has the optimal raw material composition and weight ratio.

[0055] Another object of the present invention is to provide a method for preparing the Chinese medicine preparation, which can effectively enrich the active ingredients in the Chinese medicine raw materials and has the characteristics of simple process, low cost, non-toxicity, and convenient industrial production.

[0056] The present invention also provides a method for preparing the above-mentioned Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, which comprises:

[0057] The Chinese medicinal raw materials in the formula amount are weighed respectively, decocted in water for extraction, filtered, the filtrates are combined, and concentrated under reduced pressure to obtain a thick paste, the thick paste is dried to obtain a dry paste, and auxiliary materials are added to obtain the product.

[0058] In some preferred embodiments of the present invention, the Chinese medicinal raw materials are soaked for 0.5-4 hours before extraction, the weight of water added for decoction is 5-10 times the weight of the Chinese medicinal raw materials, the number of extractions is 2-4 times, the extraction time each time is 0.5-2 hours, the concentration temperature is controlled at no more than 80°C, and the drying temperature is controlled at no more than 70°C.

[0059] In some preferred embodiments of the present invention, the weight of water added for decoction is 6 times the weight of the Chinese medicinal raw material, and extraction is performed twice, each time for 1 hour, and the medicinal materials are soaked for half an hour before extraction; the concentration temperature is controlled at no more than 70°C, and the drying temperature is controlled at no more than 60°C.

[0060] Another object of the present invention is to provide a pharmaceutical preparation for treating chronic atrophic gastritis with intestinal metaplasia based on the above-mentioned Chinese medicine composition, which can be conveniently used in clinical practice, ensure the safety of the medicine, be quality-controlled, and fully exert its therapeutic effect.

[0061] The present invention also provides a pharmaceutical preparation of the Chinese medicine composition obtained by preparing the above-mentioned Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and / or the above-mentioned Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, wherein the pharmaceutical preparation comprises the Chinese medicine composition and pharmaceutically acceptable excipients.

[0062] The pharmaceutically acceptable excipients may include any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, flavoring agent, disintegrant, lubricant, binder, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier, etc.

[0063] In some preferred embodiments of the present invention, the Chinese medicine preparation can be formulated into a solid, semisolid, liquid or gaseous preparation, including tablets, capsules, powders, granules, ointments, oral liquid preparations, suppositories, injections, inhalants, gels, microspheres and aerosols. Typical routes of administration of such drugs or health care compositions include oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal or intranasal administration.

[0064] In some preferred embodiments of the present invention, the Chinese medicine preparation is an oral preparation, preferably an oral solid, semisolid or liquid preparation, including tablets, capsules, powders, granules, oral liquid preparations, and gels.

[0065] For the above-mentioned oral preparations, one or more of the following substances may be present: binders, such as carboxymethyl cellulose, ethyl cellulose, cyclodextrin, microcrystalline cellulose, tragacanth gum or gelatin; excipients, such as starch, lactose or dextrin; disintegrants, such as alginic acid, sodium alginate, corn starch, etc.; lubricants, such as magnesium stearate; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; flavorings, such as mint, methyl salicylate or orange flavoring; and coloring agents, etc.

[0066] In some cases, the Chinese medicine preparation may also be an injection to achieve faster therapeutic effects, or it may be suitable for patients who are not convenient to take the medicine orally.

[0067] In some preferred embodiments of the present invention, the Chinese medicine preparation is a granule, which has the characteristics of a long shelf life, high patient acceptance, ease of use, and rapid therapeutic effect. In particular, when the Chinese medicine preparation is a granule, under the same dosage, due to the characteristics of requiring less excipients and being more effective in the stomach, it can produce a better therapeutic effect than other conventional oral solid preparations such as tablets, pills, and capsules. In addition, the Chinese medicine granule preparation has a longer shelf life and lower excipient usage than oral liquid preparations. In other words, it is optimal for the Chinese medicine preparation of the present invention to be selected as a granule.

[0068] In some preferred embodiments of the present invention, the excipient of the granules is one or more of lactose, dextrin or soluble starch.

[0069] In some preferred embodiments of the present invention, the excipient is lactose. Preferably, the drug-excipient ratio of the traditional Chinese medicine component to the excipient is 1:1-4:1, preferably 3:1.

[0070] Another object of the present invention is to provide a use of the Chinese medicine composition in preparing a medicine, which can effectively exert the therapeutic effect of the Chinese medicine composition and has a good therapeutic effect on various types of chronic atrophic gastritis with intestinal metaplasia.

[0071] The present invention provides the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and / or the preparation method of the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, and the use of the obtained traditional Chinese medicine composition in preparing medicines and / or preparations for preventing and / or treating chronic atrophic gastritis.

[0072] The present invention provides the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and / or the preparation method of the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, and the use of the obtained traditional Chinese medicine composition in preparing drugs and / or preparations for preventing and / or treating intestinal metaplasia.

[0073] The present invention provides the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and / or the preparation method of the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, and the use of the obtained traditional Chinese medicine composition in preparing drugs and / or preparations for preventing and / or treating chronic atrophic gastritis with intestinal metaplasia.

[0074] The Chinese medicine composition can also be used to prepare medicines for treating epigastric distension and pain, belching, acid reflux, noisy stomach, poor appetite, fatigue, irritability, dry mouth and bitter taste, red tongue with yellow fur or ecchymosis, and deep and stringy pulse caused by spleen deficiency and qi stagnation, stomach yin deficiency, mixed cold and heat, and toxic blood stasis.

[0075] The above components and proportions provided by the present invention have been clearly described and will not be repeated here.

[0076] To further illustrate the present invention, a Chinese medicine composition provided by the present invention, its preparation method and application are described in detail below with reference to examples.

[0077] Examples 1-9

[0078] The formula of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia of Example 1-9 is shown in Table 1.

[0079] Table 1: Formulas of Chinese medicine compositions of Examples 1-9

[0080]

[0081]

[0082] The preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia in Example 1-9 includes: weighing each medicinal material according to the formula amount of Example 1-9, decocting and extracting with water, the mass of water added during decoction is 6 times the total mass of each medicinal material, extracting twice, each time for 1 hour, and soaking the medicinal materials for 0.5 hour before extraction; filtering after each extraction, combining the filtrates, and concentrating under reduced pressure at a temperature not exceeding 70°C to obtain a thick paste, drying the thick paste at a temperature not exceeding 60°C to obtain a dry paste, crushing the dry paste, adding lactose at a drug-excipient ratio of 3:1 based on the amount of the dry paste, and preparing granules using a dry granulation method.

[0083] Examples 11-19

[0084] The formula of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia in Examples 11-19 is the same as that in Examples 1-9.

[0085] The preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia of Examples 11-19 comprises: weighing each medicinal material according to the formula amount of Examples 1-9, decocting and extracting with water, the mass of water added during decoction being 5 times the total mass of each medicinal material, extracting 4 times, each time for 0.5 hour, and soaking the medicinal materials for 4.5 hours before extraction; filtering after each extraction, combining the filtrates, and concentrating under reduced pressure at a temperature not exceeding 80°C to obtain a thick paste, spray drying the thick paste at a temperature not exceeding 70°C to obtain a dry paste powder, adding lactose at a drug-excipient ratio of 4:1 based on the amount of dry paste, using 75% ethanol as a wetting agent, preparing granules, and filling them into capsules to prepare capsules.

[0086] Examples 21-29

[0087] The formula of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia of Examples 21-29 is the same as that of Examples 1-9.

[0088] The preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia of Examples 21-29 comprises: weighing each medicinal material according to the formula amount of Examples 1-9, decocting and extracting with water, the mass of water added during decoction being 10 times the total mass of each medicinal material, extracting 3 times, each time for 2 hours, and soaking the medicinal materials for 1.5 hours before extraction; filtering after each extraction, combining the filtrates, and concentrating under reduced pressure at a temperature not exceeding 75°C to obtain a thick paste, drying the thick paste at a temperature not exceeding 70°C to obtain a dry paste, crushing the dry paste, adding soluble starch at a drug-excipient ratio of 1:1 based on the amount of the dry paste, using 95% ethanol as a wetting agent, preparing granules, and then adding magnesium stearate and microcrystalline cellulose, pressing into tablets, and preparing tablets.

[0089] Examples 31-39

[0090] The formulas of the traditional Chinese medicine compositions for treating chronic atrophic gastritis with intestinal metaplasia of Examples 31-39 are the same as those of Examples 1-9.

[0091] The preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia of Examples 31-39 comprises: weighing each medicinal material according to the formula amount of Examples 1-9, extracting with ethanol reflux, decocting under 10 times the solvent, extracting twice, each time for 1 hour, and soaking the medicinal materials for 0.5 hour before extraction; filtering after each extraction, combining the filtrates, and concentrating under reduced pressure at a temperature not exceeding 80°C to obtain a thick paste, drying the thick paste at a temperature not exceeding 60°C to obtain a dry paste, crushing the dry paste, and adding dextrin at a drug-excipient ratio of 2:1 based on the amount of the dry paste to prepare granules.

[0092] Examples 41-49

[0093] The formulas of the traditional Chinese medicine compositions for treating chronic atrophic gastritis with intestinal metaplasia in Examples 41-49 are the same as those in Examples 1-9.

[0094] The preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia of Examples 41-49 comprises: weighing each medicinal material according to the formula amount of Examples 1-9, extracting with ethanol reflux, decocting under 10 times the solvent, extracting twice, each time for 1 hour, and soaking the medicinal materials for 0.5 hour before extraction; filtering after each extraction, combining the filtrates, and concentrating under reduced pressure at a temperature not exceeding 80°C to obtain a thick paste, drying the thick paste at a temperature not exceeding 65°C to obtain a dry paste, crushing the dry paste, and preparing orally disintegrating tablets.

[0095] Examples 51-59

[0096] The formulas of the traditional Chinese medicine compositions for treating chronic atrophic gastritis with intestinal metaplasia in Examples 51-59 are the same as those in Examples 1-9.

[0097] The preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia of Examples 51-59 comprises: weighing each medicinal material according to the formula amount of Examples 1-9, extracting by refluxing with 50% ethanol, decocting under the condition of 8 times the solvent, extracting 3 times, each time for 1.5 hours, and soaking the medicinal materials for 0.5 hours before extraction; filtering after each extraction, combining the filtrates, and concentrating under reduced pressure at a temperature not exceeding 80°C to obtain a fluid extract, adding a flavoring agent, and preparing it as an oral liquid preparation.

[0098] Comparative Example 1

[0099] The different processed products of Example 1, wherein the Atractylodes macrocephala is raw Atractylodes macrocephala and the Pinellia ternata is processed Pinellia ternata, and the contents of other ingredients and the preparation method are the same as those of Example 1.

[0100] Comparative Example 2

[0101] The formula of the Chinese medicine composition in "Analysis of risk factors for chronic atrophic gastritis and study of the efficacy and mechanism of intervention with the pungent opening, bitter descending and regulating pivot prescription": 10g of Pinellia ternata, 10g of Scutellaria baicalensis, 8g of Coptis chinensis, 10g of dried ginger, 10g of Curcuma aromatica, 10g of stir-fried Atractylodes macrocephala, 10g of stir-fried Atractylodes macrocephala, 15g of Astragalus membranaceus, 20g of Hedyotis diffusa, 20g of Scutellaria barbata, 10g of Salvia miltiorrhiza, 10g of Dendrobium candidum, 10g of Pseudostellaria pseudoginseng, 6g of stir-fried barley sprout, 6g of stir-fried malt, 10g of Citrus aurantium immaturus, 10g of Magnolia officinalis, 10g of Curcuma zedoaria, 3g of ginger, and 6g of jujube.

[0102] Comparative Example 3

[0103] The formula of the Chinese medicine combination in "30 cases of chronic atrophic gastritis treated with Banxia Xiexin Decoction combined with acupoint injection": 12g of processed Pinellia, 10g of Codonopsis, 9g of Coptis, 9g of Scutellaria, 9g of Dry Ginger, 6g of Roasted Licorice, 4 jujubes, 15g of Curcuma, 15g of Salvia miltiorrhiza, 20g of Astragalus, and 12g of Atractylodes.

[0104] Comparative Example 4

[0105] Formula of Chinese medicine composition: 18g of Coptis chinensis, 18g of dried ginger, 15g of Scutellaria baicalensis, 18g of Pinellia ternata, 5g of Astragalus membranaceus, 20g of Codonopsis pilosula, 20g of stir-fried Atractylodes macrocephala, 8g of Dendrobium candidum, 5g of Curcuma aromatica, 5g of Salvia miltiorrhiza, 15g of Curcuma zedoaria, 10g of Hedyotis diffusa, 5g of Citrus aurantium, and 3g of stir-fried malt.

[0106] Comparative Example 5

[0107] Formula of Chinese medicine composition: 20g of Coptis chinensis, 5g of dried ginger, 3g of Scutellaria baicalensis, 5g of Pinellia ternata, 30g of Astragalus membranaceus, 20g of Codonopsis pilosula, 15g of stir-fried Atractylodes macrocephala, 5g of Dendrobium candidum, 15g of Curcuma aromatica, 15g of Salvia miltiorrhiza, 5g of Curcuma zedoaria, 30g of Hedyotis diffusa, 30g of Citrus aurantium, and 10g of stir-fried malt.

[0108] Verification example: API composition and ratio screening experiment

[0109] 1. Animals

[0110] SPF rats, half male and half female, weighing 180-200g, aged 6-8 weeks, were randomly divided into a control group and a modeling group. During the experimental period, the laboratory temperature was 21.3±0.5°C, within the range of 20-25°C, and the humidity was 54.2±3.2%, within the range of 40%-70%, meeting national standards. The control group rats were housed as usual and provided with adequate feed. The model group rats received free access to a 120μg / ml aqueous solution of MNNG (1-methyl-3-nitro-1-nitrosoguanidine) daily for 26 weeks. They were also gavaged with a 20mg / ml sodium salicylate solution twice weekly and fasted for 16-18 hours twice weekly. At week 26 of modeling, three control and modeling rats, both male and female, were randomly killed and examined for gastric histopathological changes to confirm successful modeling.

[0111] 2. Drugs and grouping

[0112] Set up the following animal groups:

[0113] Group 1: Example 1;

[0114] Group 2: Example 2;

[0115] Group 3: Example 3;

[0116] Group 4: Comparative Example 1;

[0117] Group 5: Comparative Example 2;

[0118] Group 6: Comparative Example 3;

[0119] Group 7: Comparative Example 4;

[0120] Group 8: Comparative Example 5.

[0121] The raw materials of each group mentioned above were prepared into granules according to the method of Example 1, and then formulated into suspensions with distilled water.

[0122] 3. Administer medication

[0123] At week 27, the model rats were randomly divided into 10 groups according to body weight: blank group, model group, group 1, group 2, group 3, group 4, group 5, group 6, group 7, and group 8.

[0124] The normal control group and the model group were gavaged with drinking water every day, and the other groups were gavaged with 10 ml / kg of the corresponding drugs. The results were observed after 8 weeks of administration.

[0125] 4. Results

[0126] 4.1 Effects of each group on gastric juice volume, acidity and pepsin activity in CAG rat model

[0127] Compared with the blank group, the model group had a significantly decreased gastric fluid volume (P < 0.01). Compared with the model group, the gastric fluid volume in treatment groups 1 and 2 increased significantly (P < 0.05), with Group 1 being greater than Group 2. No significant changes were observed in the other treatment groups. Compared with the blank group, the gastric fluid acidity in the model group was significantly decreased (P < 0.01). Compared with the model group, the gastric fluid acidity in treatment groups 1, 2, and 3 was significantly increased (P < 0.05), with Group 1 > Group 2 > Group 3. There were no significant differences in gastric fluid acidity among the other groups. Compared with the blank group, the model group had a significantly decreased pepsin activity (P < 0.01). Compared with the model group, the pepsin activity in treatment groups 1, 2, 3, and 4 was significantly increased (P < 0.05), with Group 1 > Group 2 > Group 3 > Group 4. The results are shown in Table 2.

[0128] Table 2 Effects of gastric juice volume, acidity and pepsin activity in each group of CAG rat models

[0129]

[0130] Note: **P<0.01 compared with the blank group; △P<0.05 compared with the model group

[0131] It should be noted that decreased gastric fluid volume is a typical pathological manifestation of CAG. Atrophy of gastric mucosal glands leads to a decrease in the number of chief and parietal cells, a decrease in gastric acid and pepsinogen secretion, and a direct impact on gastric fluid secretion. Reduced gastric fluid volume impairs gastric digestion, prolonging food retention and further damaging the gastric mucosa. It also reduces the ability of the acidic environment in the stomach to kill pathogens, exacerbating inflammation and the progression of intestinal metaplasia.

[0132] Normal gastric acidity is key to maintaining pepsin activity and bactericidal function. Patients with chronic atrophic gastritis have insufficient gastric acid secretion, which leads to increased gastric pH and the formation of a microenvironment that is conducive to the colonization of Helicobacter pylori. H. pylori infection is closely related to the "inflammation-cancer transformation" of chronic atrophic gastritis with intestinal metaplasia. Reduced gastric acidity can also promote the proliferation of enterochromaffin-like cells by activating the gastrin feedback mechanism, increasing the risk of gastric cancer. Restoring gastric acidity can inhibit H. pylori proliferation and block the process of inflammation and cancer.

[0133] Pepsin is secreted by gastric chief cells, and its activity depends on gastric acid for activation. Patients with chronic atrophic gastritis have reduced pepsinogen secretion, and the low-acid environment prevents the conversion of pepsinogen to its active form, further impairing protein digestion. Reduced pepsin activity is associated with impaired gastric mucosal repair. Long-term incomplete protein digestion may lead to nutritional deficiencies, exacerbating mucosal atrophy and intestinal metaplasia. Increasing pepsin activity can help improve digestive function and promote mucosal repair.

[0134] 4.2 Changes in the thickness of the muscularis mucosa (L1), mucosal thickness (L2), and L2 / L1 ratio of rats in each group

[0135] The experimental results showed that the treatment groups 1, 2, 3, and 4 all showed varying degrees of improvement in gastric atrophy. With the exception of groups 5, 6, 7, and 8, the mucosal thickness increased to varying degrees, with statistically significant differences (P < 0.05 or P < 0.01). Compared with the model group, the thickness of the muscularis mucosa in groups 1, 2, 3, and 4 all decreased to varying degrees, with a significant increase (P < 0.05). The results are shown in Table 3.

[0136] Table 3 Mucosal muscularis mucosa thickness (L1) and mucosal thickness (L2) of rats in each group

[0137] Group n Muscularis mucosa thickness (L1) Mucosal thickness (L2) Blank group 8 59.38±5.28 633.50±41.00 Model Group 8 102.63±19.78** 393.00±51.00* 1 group 8 <![CDATA[68.50±4.25 △ ]]> <![CDATA[502.00±53.50 △ ]]> 2 groups 8 <![CDATA[68.25±9.31 △ ]]> <![CDATA[510.50±18.63 △ ]]> 3 groups 8 <![CDATA[72.00±6.50 △ ]]> <![CDATA[531.88±53.56 △ ]]> 4 groups 8 <![CDATA[74.50±5.38 △ ]]> <![CDATA[518.88±47.91 △ ]]> 5 groups 8 90.75±5.50 439.38±65.72 6 groups 8 87.00±8.50 437.75±57.25 7 groups 8 85.00±12.50 451.38±54.88 8 groups 8 86.00±8.00 437.38±46.53

[0138] Note: Compared with the normal group, **P<0.01; compared with the model group, △P<0.05.

[0139] In chronic atrophic gastritis with intestinal metaplasia, thickening of the muscularis mucosa (L1) reflects fibrosis and gastric motility disorders, while thinning of the mucosa (L2) indicates glandular atrophy and loss of function. A decreased L2 / L1 ratio indicates an imbalance in "mucosal atrophy and fibrosis," a sign of disease progression and increased risk of cancer. The traditional Chinese medicine composition of the present invention inhibits fibrosis (decreases L1), promotes glandular regeneration (increases L2), and improves the L2 / L1 ratio, demonstrating morphologically that it reverses mucosal atrophy and repairs gastric mucosal structure, thereby blocking the inflammation-to-cancer transformation process.

[0140] 4.3 Changes in the number of glands in each group of rats

[0141] The experimental results showed that the number of glands in the model group was significantly lower than that in the blank group, with a statistically significant difference (P < 0.01). The number of glands in the implementation groups 1, 2, 3, and 4 was significantly higher than that in the model group, with a statistically significant difference (P < 0.05). The results are shown in Table 4.

[0142] Table 4 Number of gastric mucosal glands in rats in each group

[0143] Group n Number of glands Blank group 10 28.00±1.25 Model Group 10 15.50±2.13** 1 group 10 <![CDATA[25.00±2.75 △ ]]> 2 groups 10 <![CDATA[20.75±2.94 △ ]]> 3 groups 10 <![CDATA[20.00±2.25 △ ]]> 4 groups 10 <![CDATA[19.88±1.41 △ ]]> 5 groups 10 18.25±2.44 6 groups 10 18.00±1.75 7 groups 10 19.63±1.13 8 groups 10 19.13±1.63

[0144] Note: Compared with the normal group, **P<0.01; compared with the model group, △P<0.05

[0145] A decrease in glandular number is a core pathological feature of chronic atrophic gastritis with intestinal metaplasia, directly reflecting the decline in gastric mucosal secretory function and the expansion of the intestinal metaplasia area. Glandular loss exacerbates insufficient secretion of gastric acid and pepsin, promoting inflammation and carcinogenesis. The Chinese medicine composition of the present invention promotes glandular regeneration by replenishing qi and nourishing yin (such as Astragalus and Dendrobium), and improves mucosal microcirculation by removing blood stasis and detoxifying (such as Salvia miltiorrhiza and Curcuma), thereby increasing glandular number, reversing atrophy from both functional and structural perspectives and exerting a therapeutic effect.

[0146] This specific embodiment is only an explanation of the present application, and it is not a limitation of the present application. After reading this specification, those skilled in the art can make non-creative modifications to the present embodiment as needed, but as long as it is within the scope of the claims of the present application, it is protected by the patent law.

Claims

1. A Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, characterized in that: The invention comprises the following components in proportion by weight: 5-18 parts of coptis chinensis, 5-18 parts of dried ginger, 4-15 parts of scutellaria baicalensis, 5-18 parts of pinellia ternata, 9-27 parts of astragalus membranaceus, 5-18 parts of codonopsis pilosula, 5-18 parts of atractylodes macrocephala, 5-18 parts of dendrobium officinale, 5-18 parts of turmeric, 5-18 parts of salvia miltiorrhiza, 5-18 parts of zedoaria, 10-30 parts of oldenlandia diffusa and 5-18 parts of immature bitter orange.

2. The Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to claim 1, characterized in that: The invention comprises the following components in proportions by weight: 6-14 parts of coptis chinensis, 6-14 parts of dried ginger, 5-11 parts of scutellaria baicalensis, 6-14 parts of pinellia ternata, 11-19 parts of astragalus membranaceus, 6-14 parts of codonopsis pilosula, 6-14 parts of atractylodes macrocephala, 6-14 parts of dendrobium officinale, 6-14 parts of turmeric, 6-14 parts of salvia miltiorrhiza, 6-14 parts of zedoaria, 15-25 parts of oldenlandia diffusa, and 6-14 parts of immature bitter orange.

3. The Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to claim 1, characterized in that: The composition comprises the following components in parts by weight: 10 parts of Coptis chinensis, 10 parts of dried ginger, 8 parts of Scutellaria baicalensis, 10 parts of Pinellia ternata, 15 parts of Astragalus membranaceus, 10 parts of Codonopsis pilosula, 10 parts of Atractylodes macrocephala, 10 parts of Dendrobium candidum, 10 parts of Curcuma aromatica, 10 parts of Salvia miltiorrhiza, 10 parts of Curcuma zedoaria, 20 parts of Hedyotis diffusa, and 10 parts of Citrus aurantium; or 9 parts of Coptis chinensis, 6 parts of Dry Ginger, 6 parts of Scutellaria baicalensis, 6 parts of Pinellia ternata, 9 parts of Astragalus membranaceus, 6 parts of Codonopsis pilosula, 6 parts of Atractylodes macrocephala, 6 parts of Dendrobium candidum, 6 parts of Curcuma aromatica, 6 parts of Salvia miltiorrhiza, 6 parts of Curcuma zedoaria, 12 parts of Hedyotis diffusa, 6 parts of Citrus aurantium; or 12 parts of Coptis chinensis, 12 parts of dried ginger, 12 parts of Scutellaria baicalensis, 12 parts of Pinellia ternata, 17 parts of Astragalus membranaceus, 8 parts of Codonopsis pilosula, 8 parts of Atractylodes macrocephala, 8 parts of Dendrobium candidum, 8 parts of Curcuma aromatica, 8 parts of Salvia miltiorrhiza, 8 parts of Curcuma zedoaria, 18 parts of Hedyotis diffusa, 8 parts of Citrus aurantium; or 8 parts of Coptis chinensis, 8 parts of dried ginger, 6 parts of Scutellaria baicalensis, 8 parts of Pinellia ternata, 13 parts of Astragalus membranaceus, 12 parts of Codonopsis pilosula, 12 parts of Atractylodes macrocephala, 12 parts of Dendrobium candidum, 12 parts of Curcuma aromatica, 12 parts of Salvia miltiorrhiza, 12 parts of Curcuma zedoaria, 22 parts of Hedyotis diffusa, and 12 parts of Citrus aurantium.

4. The Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to any one of claims 1 to 3, characterized in that: The pinellia is clear pinellia, and the atractylodes is stir-fried atractylodes.

5. A method for preparing the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to any one of claims 1 to 4, characterized in that: The method includes: The Chinese medicinal raw materials in the formula amount are weighed respectively, decocted in water for extraction, filtered, the filtrates are combined, concentrated under reduced pressure, dried, and auxiliary materials are added to obtain the product.

6. The method for preparing the Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to claim 5, characterized in that: The Chinese medicinal raw materials are soaked and then extracted. The weight of water added in the decoction is 5-10 times the weight of the Chinese medicinal raw materials. The extraction times are 2-4 times.

7. A pharmaceutical preparation of the Chinese medicine composition obtained by the method for preparing the Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to any one of claims 1 to 4 and / or the Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to any one of claims 5 to 6, characterized in that: The pharmaceutical preparation comprises the traditional Chinese medicine composition and excipients.

8. The pharmaceutical preparation of the Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to claim 7, characterized in that: The dosage forms of the pharmaceutical preparation include tablets, capsules, powders, granules, ointments, oral liquid preparations, suppositories, injections, inhalants, gels, microspheres, and aerosols.

9. A method for preparing the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to any one of claims 1 to 4 and / or the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to any one of claims 5 to 6, and use of the traditional Chinese medicine composition in preparing a medicament and / or preparation for preventing and / or treating chronic atrophic gastritis.

10. Use of the traditional Chinese medicine composition obtained according to the method for preparing the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to any one of claims 1 to 4 and / or the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia according to any one of claims 5 to 6 in the preparation of drugs and / or preparations for preventing and / or treating intestinal metaplasia.

Images